Case report of a patient with generalized NSCLC with high PD-L1 expression treated with pembrolizumab
Abstract
In recent years, immunotherapy has become an integral part of the treatment of advanced bronchogenic carcinoma, especially non-small cell carcinoma (NSCLC). The results of a number of studies have shown an improvement in overall survival, sometimes reaching many years, which has never been seen before in patients without proven control mutations that can be affected by targeted treatment.
At present, first-line immunotherapy is approved in the Czech Republic in patients with NSCLC only in the case of high PD-L1 >= 50 studies. However, studies show that the effect of immunotherapy in combination with chemotherapy is potentiated in suitable patients. higher expression of PD-L1 on tumor cells.
This combination has already been approved by the FDA and EMA. We can only hope that this treatment will be available for our patients in the near future.